BeyondSpring (BYSI) Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conference Dec 13, 2022 08:03AM
BeyondSpring (BYSI) Presents New Clinical Data in the Chemotherapy-Induced Neutropenia May 27, 2022 07:02AM
BeyondSpring (BYSI) Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress Sep 16, 2021 07:04AM
BeyondSpring (BYSI) to Present Three Abstracts from PROTECTIVE-2 Phase 3 Trials of Plinabulin at ASCO Jun 7, 2021 07:05AM
BeyondSpring (BYSI) Reports New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results Dec 10, 2020 08:08AM


Nov 16, 2020 07:06AM BeyondSpring (BYSI) Reports Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin
Sep 24, 2020 08:12AM BeyondSpring (BYSI) Says New Data Highlights Plinabulin as Effective Agent for Preventing Chemotherapy-Induced Neutropenia, with Potential to Reduce Clinical Resources for COVID-19
Sep 8, 2020 07:07AM BeyondSpring (BYSI) Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication
Jun 15, 2020 07:00AM BeyondSpring (BYSI) Reports Positive Topline Interim Results Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for CIN Prevention
Apr 29, 2020 08:12AM BeyondSpring (BYSI) Reports Formal Change to Primary Endpoint for Study 106 Phase 3 Superiority Clinical Trial with Plinabulin Following FDA Discussions
Dec 10, 2019 08:06AM BeyondSpring's (BYSI) Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for CIN Presented at ASH
Oct 23, 2019 08:35AM BeyondSpring (BYSI) Reports First Patient Enrollment in Global Phase 3 Clinical Trial with Plinabulin in Combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia
Mar 5, 2019 07:33AM BeyondSpring (BYSI) Presents New Data in Chemotherapy-Induced Neutropenia at ASCO-SITC
Dec 6, 2018 07:32AM BeyondSpring (BYSI) Reports Phase 3 Study 105, Evaluating Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
Oct 23, 2018 07:07AM BeyondSpring (BYSI) Announces Efficacy and Safety Data from Phase 2 Study 106 with Plinabulin for CIN Prevention
Oct 16, 2018 07:10AM BeyondSpring (BYSI) Says Lead Asset, Plinabulin, Prevents Docetaxel CIN Due to Mechanism of Action Differentiated from G-CSF